NCT00504972View on ClinicalTrials.gov

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 1, 2011

Study Completion Date

October 7, 2015

Conditions
Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

hLL1

hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER